Molecular biomedicine最新文献_第6页

Ultraviolet (UV) radiation: a double-edged sword in cancer development and therapy. 紫外线（UV）辐射：癌症发展和治疗的双刃剑。

IF 6.3

Molecular biomedicine Pub Date : 2024-10-17 DOI: 10.1186/s43556-024-00209-8

Zhen-Wei Yu, Min Zheng, Hua-Yang Fan, Xin-Hua Liang, Ya-Ling Tang

{"title":"Ultraviolet (UV) radiation: a double-edged sword in cancer development and therapy.","authors":"Zhen-Wei Yu, Min Zheng, Hua-Yang Fan, Xin-Hua Liang, Ya-Ling Tang","doi":"10.1186/s43556-024-00209-8","DOIUrl":"https://doi.org/10.1186/s43556-024-00209-8","url":null,"abstract":"It has long been widely acknowledged that ultraviolet (UV) light is an environment risk factor that can lead to cancer, particularly skin cancer. However, it is worth noting that UV radiation holds potential for cancer treatment as a relatively high-energy electromagnetic wave. With the help of nanomaterials, the role of UV radiation has caught increasing attention in cancer treatment. In this review, we briefly summarized types of UV-induced cancers, including malignant melanoma, squamous cell carcinoma, basal cell carcinoma, Merkel cell carcinoma. Importantly, we discussed the primary mechanisms underlying UV carcinogenesis, including mutations by DNA damage, immunosuppression, inflammation and epigenetic alterations. Historically limited by its shallow penetration depth, the introduction of nanomaterials has dramatically transformed the utilization of UV light in cancer treatment. The direct effect of UV light itself generally leads to the suppression of cancer cell growth and the initiation of apoptosis and ferroptosis. It can also be utilized to activate photosensitizers for reactive oxygen species (ROS) production, sensitize radiotherapy and achieve controlled drug release. Finally, we comprehensively weigh the significant risks and limitations associated with the therapeutic use of UV radiation. And the contradictory effect of UV exposure in promoting and inhibiting tumor has been discussed. This review provides clues for potential clinical therapy as well as future study directions in the UV radiation field. The precise delivery and control of UV light or nanomaterials and the wavelength as well as dose effects of UV light are needed for a thorough understanding of UV radiation.","PeriodicalId":74218,"journal":{"name":"Molecular biomedicine","volume":"5 1","pages":"49"},"PeriodicalIF":6.3,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486887/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142482512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment-resistant depression: molecular mechanisms and management. 耐药性抑郁症：分子机制与管理。

IF 6.3

Molecular biomedicine Pub Date : 2024-10-17 DOI: 10.1186/s43556-024-00205-y

Mayanja M Kajumba, Angelina Kakooza-Mwesige, Noeline Nakasujja, Deborah Koltai, Turhan Canli

{"title":"Treatment-resistant depression: molecular mechanisms and management.","authors":"Mayanja M Kajumba, Angelina Kakooza-Mwesige, Noeline Nakasujja, Deborah Koltai, Turhan Canli","doi":"10.1186/s43556-024-00205-y","DOIUrl":"10.1186/s43556-024-00205-y","url":null,"abstract":"Due to the heterogeneous nature of depression, the underlying etiological mechanisms greatly differ among individuals, and there are no known subtype-specific biomarkers to serve as precise targets for therapeutic efficacy. The extensive research efforts over the past decades have not yielded much success, and the currently used first-line conventional antidepressants are still ineffective for close to 66% of patients. Most clinicians use trial-and-error treatment approaches, which seem beneficial to only a fraction of patients, with some eventually developing treatment resistance. Here, we review evidence from both preclinical and clinical studies on the pathogenesis of depression and antidepressant treatment response. We also discuss the efficacy of the currently used pharmacological and non-pharmacological approaches, as well as the novel emerging therapies. The review reveals that the underlying mechanisms in the pathogenesis of depression and antidepressant response, are not specific, but rather involve an interplay between various neurotransmitter systems, inflammatory mediators, stress, HPA axis dysregulation, genetics, and other psycho-neurophysiological factors. None of the current depression hypotheses sufficiently accounts for the interactional mechanisms involved in both its etiology and treatment response, which could partly explain the limited success in discovering efficacious antidepressant treatment. Effective management of treatment-resistant depression (TRD) requires targeting several interactional mechanisms, using subtype-specific and/or personalized therapeutic modalities, which could, for example, include multi-target pharmacotherapies in augmentation with psychotherapy and/or other non-pharmacological approaches. Future research guided by interaction mechanisms hypotheses could provide more insights into potential etiologies of TRD, precision biomarker targets, and efficacious therapeutic modalities.","PeriodicalId":74218,"journal":{"name":"Molecular biomedicine","volume":"5 1","pages":"43"},"PeriodicalIF":6.3,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142482511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Monoclonal antibodies: From magic bullet to precision weapon. 单克隆抗体：从神奇子弹到精确武器

IF 6.3

Molecular biomedicine Pub Date : 2024-10-11 DOI: 10.1186/s43556-024-00210-1

Hassan Aboul-Ella, Asmaa Gohar, Aya Ahmed Ali, Lina M Ismail, Adham Ezz El-Regal Mahmoud, Walid F Elkhatib, Heba Aboul-Ella

{"title":"Monoclonal antibodies: From magic bullet to precision weapon.","authors":"Hassan Aboul-Ella, Asmaa Gohar, Aya Ahmed Ali, Lina M Ismail, Adham Ezz El-Regal Mahmoud, Walid F Elkhatib, Heba Aboul-Ella","doi":"10.1186/s43556-024-00210-1","DOIUrl":"10.1186/s43556-024-00210-1","url":null,"abstract":"Monoclonal antibodies (mAbs) are used to prevent, detect, and treat a broad spectrum of non-communicable and communicable diseases. Over the past few years, the market for mAbs has grown exponentially with an expected compound annual growth rate (CAGR) of 11.07% from 2024 (237.64 billion USD estimated at the end of 2023) to 2033 (679.03 billion USD expected by the end of 2033). Ever since the advent of hybridoma technology introduced in 1975, antibody-based therapeutics were realized using murine antibodies which further progressed into humanized and fully human antibodies, reducing the risk of immunogenicity. Some benefits of using mAbs over conventional drugs include a drastic reduction in the chances of adverse reactions, interactions between drugs, and targeting specific proteins. While antibodies are very efficient, their higher production costs impede the process of commercialization. However, their cost factor has been improved by developing biosimilar antibodies as affordable versions of therapeutic antibodies. Along with the recent advancements and innovations in antibody engineering have helped and will furtherly help to design bio-better antibodies with improved efficacy than the conventional ones. These novel mAb-based therapeutics are set to revolutionize existing drug therapies targeting a wide spectrum of diseases, thereby meeting several unmet medical needs. This review provides comprehensive insights into the current fundamental landscape of mAbs development and applications and the key factors influencing the future projections, advancement, and incorporation of such promising immunotherapeutic candidates as a confrontation approach against a wide list of diseases, with a rationalistic mentioning of any limitations facing this field.","PeriodicalId":74218,"journal":{"name":"Molecular biomedicine","volume":"5 1","pages":"47"},"PeriodicalIF":6.3,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142402276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ulcerative colitis: molecular insights and intervention therapy. 溃疡性结肠炎：分子研究与干预治疗。

IF 6.3

Molecular biomedicine Pub Date : 2024-10-10 DOI: 10.1186/s43556-024-00207-w

Yuqing Liang, Yang Li, Chehao Lee, Ziwei Yu, Chongli Chen, Chao Liang

{"title":"Ulcerative colitis: molecular insights and intervention therapy.","authors":"Yuqing Liang, Yang Li, Chehao Lee, Ziwei Yu, Chongli Chen, Chao Liang","doi":"10.1186/s43556-024-00207-w","DOIUrl":"10.1186/s43556-024-00207-w","url":null,"abstract":"Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by abdominal pain, diarrhea, rectal bleeding, and weight loss. The pathogenesis and treatment of UC remain key areas of research interest. Various factors, including genetic predisposition, immune dysregulation, and alterations in the gut microbiota, are believed to contribute to the pathogenesis of UC. Current treatments for UC include 5-aminosalicylic acids, corticosteroids, immunosuppressants, and biologics. However, study reported that the one-year clinical remission rate is only around 40%. It is necessary to prompt the exploration of new treatment modalities. Biologic therapies, such as anti-TNF-α monoclonal antibody and JAK inhibitor, primarily consist of small molecules targeting specific pathways, effectively inducing and maintaining remission. Given the significant role of the gut microbiota, research into intestinal microecologics, such as probiotics and prebiotics, and fecal microbiota transplantation (FMT) shows promising potential in UC treatment. Additionally, medicinal herbs, such as chili pepper and turmeric, used in complementary therapy have shown promising results in UC management. This article reviews recent findings on the mechanisms of UC, including genetic susceptibility, immune cell dynamics and cytokine regulation, and gut microbiota alterations. It also discusses current applications of biologic therapy, herbal therapy, microecologics, and FMT, along with their prospects and challenges.","PeriodicalId":74218,"journal":{"name":"Molecular biomedicine","volume":"5 1","pages":"42"},"PeriodicalIF":6.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathways regulating intestinal stem cells and potential therapeutic targets for radiation enteropathy. 调节肠干细胞的途径和辐射性肠病的潜在治疗靶点

IF 6.3

Molecular biomedicine Pub Date : 2024-10-10 DOI: 10.1186/s43556-024-00211-0

Si-Min Chen, Bing-Jie Guo, An-Qiang Feng, Xue-Lian Wang, Sai-Long Zhang, Chao-Yu Miao

{"title":"Pathways regulating intestinal stem cells and potential therapeutic targets for radiation enteropathy.","authors":"Si-Min Chen, Bing-Jie Guo, An-Qiang Feng, Xue-Lian Wang, Sai-Long Zhang, Chao-Yu Miao","doi":"10.1186/s43556-024-00211-0","DOIUrl":"10.1186/s43556-024-00211-0","url":null,"abstract":"Radiotherapy is a pivotal intervention for cancer patients, significantly impacting their treatment outcomes and survival prospects. Nevertheless, in the course of treating those with abdominal, pelvic, or retroperitoneal malignant tumors, the procedure inadvertently exposes adjacent intestinal tissues to radiation, posing risks of radiation-induced enteropathy upon reaching threshold doses. Stem cells within the intestinal crypts, through their controlled proliferation and differentiation, support the critical functions of the intestinal epithelium, ensuring efficient nutrient absorption while upholding its protective barrier properties. Intestinal stem cells (ISCs) regulation is intricately orchestrated by diverse signaling pathways, among which are the WNT, BMP, NOTCH, EGF, Hippo, Hedgehog and NF-κB, each contributing to the complex control of these cells' behavior. Complementing these pathways are additional regulators such as nutrient metabolic states, and the intestinal microbiota, all of which contribute to the fine-tuning of ISCs behavior in the intestinal crypts. It is the harmonious interplay among these signaling cascades and modulating elements that preserves the homeostasis of intestinal epithelial cells (IECs), thereby ensuring the gut's overall health and function. This review delves into the molecular underpinnings of how stem cells respond in the context of radiation enteropathy, aiming to illuminate potential biological targets for therapeutic intervention. Furthermore, we have compiled a summary of several current treatment methodologies. By unraveling these mechanisms and treatment methods, we aspire to furnish a roadmap for the development of novel therapeutics, advancing our capabilities in mitigating radiation-induced intestinal damage.","PeriodicalId":74218,"journal":{"name":"Molecular biomedicine","volume":"5 1","pages":"46"},"PeriodicalIF":6.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467144/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142402277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HJURP sustains ferroptosis sensitivity of TNBC by interacting with SLC7A11 and maintaining its function. HJURP 通过与 SLC7A11 相互作用并维持其功能，维持 TNBC 的铁蛋白沉积敏感性。

IF 6.3

Molecular biomedicine Pub Date : 2024-10-03 DOI: 10.1186/s43556-024-00208-9

Yongxia Chen, Kaili Cen, Linbo Wang, Jian Ruan, Yunlu Jia

引用次数: 0

Repurposing metabolic regulators: antidiabetic drugs as anticancer agents. 代谢调节剂的再利用：作为抗癌药物的抗糖尿病药物。

IF 6.3

Molecular biomedicine Pub Date : 2024-09-28 DOI: 10.1186/s43556-024-00204-z

Yogita Dhas, Nupur Biswas, Divyalakshmi M R, Lawrence D Jones, Shashaanka Ashili

{"title":"Repurposing metabolic regulators: antidiabetic drugs as anticancer agents.","authors":"Yogita Dhas, Nupur Biswas, Divyalakshmi M R, Lawrence D Jones, Shashaanka Ashili","doi":"10.1186/s43556-024-00204-z","DOIUrl":"https://doi.org/10.1186/s43556-024-00204-z","url":null,"abstract":"Drug repurposing in cancer taps into the capabilities of existing drugs, initially designed for other ailments, as potential cancer treatments. It offers several advantages over traditional drug discovery, including reduced costs, reduced development timelines, and a lower risk of adverse effects. However, not all drug classes align seamlessly with a patient's condition or long-term usage. Hence, repurposing of chronically used drugs presents a more attractive option. On the other hand, metabolic reprogramming being an important hallmark of cancer paves the metabolic regulators as possible cancer therapeutics. This review emphasizes the importance and offers current insights into the repurposing of antidiabetic drugs, including metformin, sulfonylureas, sodium-glucose cotransporter 2 (SGLT2) inhibitors, dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), thiazolidinediones (TZD), and α-glucosidase inhibitors, against various types of cancers. Antidiabetic drugs, regulating metabolic pathways have gained considerable attention in cancer research. The literature reveals a complex relationship between antidiabetic drugs and cancer risk. Among the antidiabetic drugs, metformin may possess anti-cancer properties, potentially reducing cancer cell proliferation, inducing apoptosis, and enhancing cancer cell sensitivity to chemotherapy. However, other antidiabetic drugs have revealed heterogeneous responses. Sulfonylureas and TZDs have not demonstrated consistent anti-cancer activity, while SGLT2 inhibitors and DPP-4 inhibitors have shown some potential benefits. GLP-1RAs have raised concerns due to possible associations with an increased risk of certain cancers. This review highlights that further research is warranted to elucidate the mechanisms underlying the potential anti-cancer effects of these drugs and to establish their efficacy and safety in clinical settings.","PeriodicalId":74218,"journal":{"name":"Molecular biomedicine","volume":"5 1","pages":"40"},"PeriodicalIF":6.3,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11436690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142333937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oncolytic adenovirus encoding decorin and CD40 ligand inhibits tumor growth and liver metastasis via immune activation in murine colorectal tumor model. 在小鼠结直肠肿瘤模型中，编码Decolin和CD40配体的溶瘤腺病毒通过免疫激活抑制肿瘤生长和肝转移。

IF 6.3

Molecular biomedicine Pub Date : 2024-09-22 DOI: 10.1186/s43556-024-00202-1

Yejing Rong, Yingjun Ning, Jianping Zhu, Pei Feng, Weixin Zhu, Xin Zhao, Zi Xiong, Chunyan Ruan, Jiachang Jin, Hua Wang, Ting Cai, Shun Zhang, Yuefeng Yang

{"title":"Oncolytic adenovirus encoding decorin and CD40 ligand inhibits tumor growth and liver metastasis via immune activation in murine colorectal tumor model.","authors":"Yejing Rong, Yingjun Ning, Jianping Zhu, Pei Feng, Weixin Zhu, Xin Zhao, Zi Xiong, Chunyan Ruan, Jiachang Jin, Hua Wang, Ting Cai, Shun Zhang, Yuefeng Yang","doi":"10.1186/s43556-024-00202-1","DOIUrl":"10.1186/s43556-024-00202-1","url":null,"abstract":"Colorectal cancer (CRC) is the second common cause of cancer mortality worldwide, and it still lacks effective approaches for relapsed and metastatic CRC. Recently, oncolytic virus has been emerged as a promising immune therapeutic strategy. In this study, we develop a novel oncolytic adenovirus, rAd.mDCN.mCD40L, which drive oncolytic activity by telomerase reverse transcriptase promoter (TERTp). rAd.mDCN.mCD40L expressed both mouse genes of decorin (mDCN) and CD40 ligand (mCD40L), and produced effective cytotoxicity in both human and mouse CRC cells. Moreover, oncolytic adenovirus mediated mDCN over-expression inhibited Met expression in vitro. In CT26 subcutaneous tumor model, intratumorally delivery of oncolytic adenoviruses could inhibit tumor growth and liver metastasis, while mDCN and/or mCD40L armed oncolytic adenoviruses produced much more impressive responses. No obvious toxicity was detected in lung, liver and spleen. Moreover, mDCN and/or mCD40L armed oncolytic adenoviruses altered the immune state to activate anti-tumor responses, including increasing CD8+ T effector cells and CD4+ memory T cells, reducing MDSCs and Tregs in peripheral blood. Furthermore, mDCN and/or mCD40L armed oncolytic adenoviruses mediated mDCN and/or mCD40L expression in tumors, and up-regulated Th1 cytokines and reduced Th2 cytokines in tumors, which will be benefit for remodeling tumor microenvironment. Importantly, rAd.mDCN.mCD40L and rAd.mCD40L prevented tumor liver metastasis much more effectively than rAd.Null and rAd.mDCN. Therefore, rAd.mDCN.mCD40L and rAd.mCD40L are promising approaches for CRC therapy.","PeriodicalId":74218,"journal":{"name":"Molecular biomedicine","volume":"5 1","pages":"39"},"PeriodicalIF":6.3,"publicationDate":"2024-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11416448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The dual role of SOX17 in the occurrence and development of early colorectal cancer. SOX17 在早期结直肠癌的发生和发展中的双重作用。

IF 6.3

Molecular biomedicine Pub Date : 2024-09-16 DOI: 10.1186/s43556-024-00201-2

Xinming Su, Jianqiao Shentu, Ruixiu Chen, Shiwei Duan

引用次数: 0

Gut microbiome influences efficacy of Endostatin combined with PD-1 blockade against colorectal cancer. 肠道微生物组影响内司他丁联合 PD-1 阻断剂对结直肠癌的疗效。

IF 6.3

Molecular biomedicine Pub Date : 2024-09-10 DOI: 10.1186/s43556-024-00200-3

Jie Xu, Yaomei Tian, Binyan Zhao, Die Hu, Siwen Wu, Jing Ma, Li Yang

{"title":"Gut microbiome influences efficacy of Endostatin combined with PD-1 blockade against colorectal cancer.","authors":"Jie Xu, Yaomei Tian, Binyan Zhao, Die Hu, Siwen Wu, Jing Ma, Li Yang","doi":"10.1186/s43556-024-00200-3","DOIUrl":"10.1186/s43556-024-00200-3","url":null,"abstract":"The combination of anti-angiogenic drugs and immune checkpoint inhibitors (ICIs) in the treatment of tumors is emerging as a way to improve ICIs-resistant tumor therapy. In addition, gut microbes (GMs) are involved in angiogenesis in the tumor microenvironment and are also associated with the antitumor function of immune checkpoint inhibitors. However, it is unclear whether gut microbes have a role in anti-tumor function in the combination of anti-angiogenic drugs and immune checkpoint inhibitors for cancer treatment. Endostatin, an angiogenesis inhibitor, has been widely used as an antiangiogenic therapy for cancer. We showed that combined therapy with an adenovirus encoding human endostatin, named Ad-E, and PD-1 blockade dramatically abrogated MC38 tumor growth. The structure of intestinal microbes in mice was changed after combination treatment. We found that the antitumor function of combination therapy was inhibited after the elimination of intestinal microbes. In mice with depleted microbiota, oral gavage of Bacteroides fragilis salvaged the antitumor effects of combination Ad-E and αPD-1 monoclonal antibody (mAb) to a certain extent. Further, Bacteroides fragilis could improve CD3+T cells, NK cells, and IFNγ+CD8+ T cells in the tumor microenvironment to inhibit tumor growth. Besides, Bacteroides fragilis might restore antitumor function by down-regulating isobutyric acid (IBA). Our results suggested that GMs may be involved in the combination of Ad-E and αPD-1 mAb for cancer treatment, which has oncological implications for tumor growth dynamics and cancer immune surveillance.","PeriodicalId":74218,"journal":{"name":"Molecular biomedicine","volume":"5 1","pages":"37"},"PeriodicalIF":6.3,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11383918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0